July 21, 2021

Minaris will be the commercial manufacturer in Europe for Skysona™, bluebird bio's gene therapy for CALD

MUNICH, Germany – July 21, 2021 - Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing organization (CDMO) for the cell and gene therapy industry, will be the commercial manufacturer in Europe for SkysonaTM (elivaldogene autotemcel, Lenti-D™), a product of bluebird bio, Inc. Today, the European Commission (EC) has granted marketing authorization for SkysonaTM, the first and only gene therapy for patients with Early Cerebral Adrenoleukodystrophy (CALD), a life-threatening progressive neurodegenerative disease.

“We are proud to contribute to the fight against this devastating disease in children and to support bluebird bio also with their second commercial product”, said Dusan Kosijer, CEO of Minaris Regenerative Medicine GmbH.

“Minaris is our long-standing partner for bringing gene therapies to patients in Europe,” said Andrew Obenshain, president, severe genetic diseases, bluebird bio. “Our collaboration will be integral as we work to provide SkysonaTM to the community who faces the rapid and irreversible effects of CALD.”

In 2016, Minaris and bluebird bio entered into a strategic manufacturing partnership for commercial production of ZyntegloTM for transfusion-dependent β-thalassemia (TDT) and SkysonaTM for CALD in Europe. In 2020, the companies expanded their manufacturing partnership to include late stage and commercial drug product manufacturing both in Europe and the USA (at Minaris Regenerative Medicine, LLC) of LentiGlobinTM for the treatment of patients with sickle cell disease (SCD).

About Minaris Regenerative Medicine

Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. We offer our clients high value clinical and commercial manufacturing services, development solutions, and technologies. We are pioneers in the field with more than 20 years’ experience providing outstanding quality and reliability. Our facilities in North America, Europe, and Asia allow us to supply patients worldwide with life-changing therapies. Minaris Regenerative Medicine is wholly owned by Showa Denko Materials Co., Ltd.

For more information, please visit www.rm.minaris.com

Please read the German press release here/Pressemitteilung auf Deutsch

Media Contact Info:

*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, fomerly PCT or PCT Cell Therapy Services), apceth Biopharma GmbH, and Hitachi Chemical Co., Ltd. have been renamed Minaris Regenerative Medicine and are part of the Resonac Group.

Stay up to date
on the latest news